Cancer-Targeting Compound 1 |
| Catalog No.GC33138 |
Cancer-Targeting Compound 1 est utilisé dans la recherche sur le cancer lié aux hormones, extrait du brevet WO 2008021331 A2.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1007581-62-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Cancer-Targeting Compound 1 is used in the research of hormone-?related cancer, extracted from patent WO 2008021331 A2.
Cancer-Targeting Compound 1 is useful for the research of hormone-related conditions including contraception, treating or preventing fibroids, endometriosis, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, or hormone-dependent carcinomas, providing hormone replacement therapy, stimulating food intake or synchronizing estrus[1].
[1]. Thomas, Joseph, et al. OXAZOLIDONE DERIVATIVES AS PR MODULATORS. WO 2008021331 A2.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *